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Comparison of human adult stem cells from
adipose tissue and bone marrow in the treatment
of experimental autoimmune encephalomyelitis
Julie A Semon1, Catherine Maness2, Xiujuan Zhang1, Steven A Sharkey3, Marc M Beuttler1, Forum S Shah4,
Amitabh C Pandey1, Jeffrey M Gimble4, Shijia Zhang1,3, Brittni A Scruggs1,3, Amy L Strong1, Thomas A Strong1
and Bruce A Bunnell1,3*

Abstract
Introduction: While administration of ex vivo culture-expanded stem cells has been used to study immunosuppressive
mechanisms in multiple models of autoimmune diseases, less is known about the uncultured, nonexpanded stromal
vascular fraction (SVF)-based therapy. The SVF is composed of a heterogeneous population of cells and has been used
clinically to treat acute and chronic diseases, alleviating symptoms in a range of tissues and organs.
Methods: In this study, the ability of human SVF cells was compared with culture-expanded adipose stem cells
(ASCs) and bone-derived marrow stromal cells (BMSCs) as a treatment of myelin oligodendrocyte glycoprotein
(35–55)-induced experimental autoimmune encephalitis in C57Bl/6J mice, a well-studied multiple sclerosis model (MS).
A total of 1 × 106 BMSCs, ASCs, or SVF cells were administered intraperitoneally concomitantly with the induction of
disease. Mice were monitored daily for clinical signs of disease by three independent, blinded investigators and rated
on a scale of 0 to 5. Spinal cords were obtained after euthanasia at day 30 and processed for histological staining using
luxol fast blue, toluidine blue, and hematoxylin and eosin to measure myelin and infiltrating immune cells. Blood
was collected from mice at day 30 and analyzed by enzyme-linked immunosorbent assay to measure serum levels of
inflammatory cytokines.
Results: The data indicate that intraperitoneal administration of all cell types significantly ameliorates the severity of
disease. Furthermore, the data also demonstrate, for the first time, that the SVF was as effective as the more commonly
cultured BMSCs and ASCs in an MS model. All cell therapies also demonstrated a similar reduction in tissue damage,
inflammatory infiltrates, and sera levels of IFNγ and IL-12. While IFNγ levels were reduced to comparable levels between
treatment groups, levels of IL-12 were significantly lower in SVF-treated than BMSC-treated or ASC-treated mice.
Conclusions: Based on these data, it is evident that SVF cells have relevant therapeutic potential in an animal model
of chronic MS and might represent a valuable tool for stem cell-based therapy in chronic inflammatory disease of the
central nervous system. SVF offers advantages of direct and rapid isolation procedure in a xenobiotic-free environment.
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Introduction
Adult marrow stromal cells, also referred to as mesenchymal stromal/stem cells (MSCs), have been used for
cell therapy and in tissue engineering because of their
ability to differentiate into multiple mesenchymal and
nonmesenchymal lineages in vitro, their immune modulatory effects both in vivo and in vitro, and their ability
to home to sites of tissue damage [1,2]. MSCs have been
isolated from several tissues, including the bone marrow,
adipose tissue, umbilical cord blood, liver, synovium,
skeletal muscle, kidney, skin tissue, lung, and intestinal
tract [3-7]. Currently, MSCs derived from different
sources are being utilized in clinical studies for the treatment of several diseases and injuries such as myocardial
infarction, osteogenesis imperfecta, graft-versus-host disease, Crohn’s disease, spinal cord injury, multiple sclerosis (MS), and diabetes [8,9]. Although the optimal
dosage of MSCs in clinical applications is still undetermined, the general criteria is 1 × 106 to 2 × 106 MSCs/kg
body weight per injection, which makes using primary
MSCs difficult for clinical use [10].
Since a large number of cells are often required for clinical and basic research studies, the primary cultures need
to be ex vivo expanded for multiple passages on tissue culture substrates. Typically, MSCs can undergo 24 to 40
population doublings in culture before reaching senescence [11,12]. However, after the initial culture period,
MSCs progressively lose their multipotentiality [13,14].
Fetal bovine serum (FBS), which contains a high content
of growth factors as well as nutritional and physiochemical compounds required for cell maintenance and growth,
is typically used at 10 to 20% (v/v) in media. Despite its
common use, FBS is ill-defined and presents numerous
potential problems for the expansion of MSCs [15-19].
Owing to the concerns of using FBS, particularly for clinical therapy, attempts have been made to develop defined
serum-free media. Most of these media have been inadequate, with cells growing at a slower proliferative rate,
with minimal passages, and still using serum-based media
for initial isolation and expansion phases [20,21].
The frequency of MSCs in bone marrow is very low.
MSCs represent 0.01 to 0.001% of human bone marrow
mononuclear cells [22,23]. However, recent studies report that MSCs are found at a higher frequency in adipose tissue, yielding 100 to 500 times more cells per
tissue volume [24,25]. These adipose stem cells (ASCs)
have similar self-renewal abilities, common surface epitopes, growth kinetics, and cytokine expression profiles
to bone-derived marrow stromal cells (BMSCs), but they
are not associated with the morbidity, pain, or low yield
[3,5,26]. In addition, recent data indicate that ASCs are
potently immunomodulatory, induce angiogenesis, and
are multipotent, making them an appealing alternative
to BMSCs [24-29].
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Despite the promise of ASCs, the need for ex vivo cellular expansion is still a significant obstacle. A more direct procedure, for which adipose tissue is uniquely
suited, is the administration of a nonexpanded cellular
fraction, the stromal vascular fraction (SVF). Adipose
tissue is easy to obtain in large quantities and should,
therefore, be able to provide a readily available source of
stromal stem cells in numbers sufficient to use clinically
or to study their biology without culturing cells. Antiinflammatory and regenerative effects of nonexpanded
SVF cells have yielded promising results in canine osteoarthritis and equine tendon ligament injuries [30]. With
encouraging outcomes in clinical trials [30], it is essential to examine the effects and mechanisms of SVF, especially in comparison with BMSC and ASC therapy, in
models of autoimmune disease.
MS is an autoimmune disease characterized by inflammatory demyelinating lesions, extensive mononuclear cell
infiltration into the central nervous system (CNS), and
loss of motor function. Despite improved understanding
of the mechanisms by which MS is manifested, current
treatment options for this disease – such as interferon
(IFN)-1α, IFN-1β, glatiramer acetate, fingolimod, mitoxantrone, and natalizumab – have limited efficacy in providing symptomatic relief and complete remission, especially
in patients affected with the chronic form of MS [31,32].
The application of adult stem cells as a potential treatment in MS patients is of interest, especially for patients
who do not respond to the pharmacologic immunosuppression regimens with steroids or corticotropin.
Myelin oligodendrocyte glycoprotein (35–55)-induced
experimental autoimmune encephalitis (EAE) in C57Bl/6J
mice correlates with chronic, progressive MS and is an appropriate model to investigate the effects of treatment
with BMSCs, ASCs, or SVF. While it has been reported
that mesenchymal lineage stem cells from the bone marrow have a therapeutic impact in the EAE model, only
one study to date has investigated murine ASCs, with no
studies investigating the role of human ASCs or SVF [33].
The goal of this study was to directly compare human
SVF cells with human BMSCs and ASCs as interventions
for disease progression in the EAE model.

Methods
Cell isolation and culture
Bone-derived mesenchymal stem cells

MSCs from normal healthy donors were obtained from
the Tulane Center for the Stem Cell Research and Regenerative Medicine (New Orleans, LA, USA). The cells
were prepared from four individual donors with written,
informed consent under protocols approved by Tulane
Biomedical Institutional Review Board.
In brief, bone marrow aspirates were taken from the
iliac crest of normal adult donors. Nucleated cells were
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isolated using a density gradient (Ficol-Paque; Amersham
Pharmacia Biotech, Milwaukee, WI, USA) and resuspended in complete culture medium (CCM): α-modified
Eagle’s medium (GIBCO/BRL, Grand Island, NY, USA);
20% FBS (lot selected for rapid growth; Atlanta Biologicals,
Norcross, GA, USA); 100 units/ml penicillin (GIBCO/
BRL); 100 μg/ml streptomycin (GIBCO/BRL); and 2 mM
L-glutamine (GIBCO/BRL). Cells (4 × 107 to 13 × 107) were
then plated in 20 ml medium in a 150-cm2 culture dish
and incubated at 37°C with 5% humidified CO2. After
24 hours, nonadherent cells were removed. Adherent
cells were washed twice with phosphate-buffered saline
(PBS, pH 7.4) and incubated with fresh medium. After
5 to 7 days, the cells were harvested with 0.25% trypsin/1 mM ethylenediamine tetraacetic acid (EDTA) for
about 5 minutes at 37°C and then replated at approximately 3 to 100 cells/cm2 in an inter-connecting flask
system (Cell Factory; Nunc, Rochester, NY, USA). When
the cultures reached 70% confluence, the cells (passage 1)
were harvested with trypsin/EDTA, resuspended at 1 ×
106 cells/ml in α-modified Eagle’s medium with 5% dimethyl sulfoxide and 30% FBS, frozen in 1 ml aliquots
overnight at −80°C, and then stored in liquid nitrogen.
For cell expansion, frozen vials of passage-1 MSCs were
thawed, plated in 25 ml complete MSC medium in a
150-cm2 culture dish (Nunc), and incubated at 37°C
with 5% humidified CO2. After 24 hours, the medium
was removed and adherent, viable cells were washed twice
with PBS, harvested with EDTA, replated at 100 cells/cm2
in CCM, and incubated with a medium change every 3 to
4 days. For all experiments, subconfluent cells (≤70% confluent) between passages 2 and 6 were used.
Stromal vascular fraction

The SVF was obtained from the subcutaneous white adipose tissue from three donors undergoing elective liposuction procedures. Tissues were washed three to four times
with PBS and suspended in an equal volume of PBS supplemented with 1% bovine serum and 0.1% collagenase type I
(Worthington Biochemical Corporation, Lakewood, NJ,
USA) prewarmed to 37°C. The tissue was placed in a shaking water bath at 37°C with continuous agitation for 60 minutes and centrifuged for 5 minutes at 300 to 500 × g at
room temperature. The supernatant, containing mature
adipocytes, was aspirated. The pellet was identified as the
SVF cell population. Portions of the SVF cells were resuspended in cryopreservation medium (10% dimethyl sulfoxide, 10% Dulbecco’s modified Eagle’s medium/F-12 Ham’s,
80% FBS), frozen at −80°C in an ethanol-jacketed closed
container, and subsequently stored in liquid nitrogen
[34,35]. All protocols were reviewed and approved by the
Pennington Biomedical Research Center Institutional Review Board and all human participants provided written informed consent.

Page 3 of 11

Frozen vials of approximately 106 SVF were thawed,
suspended in 50 ml prewarmed CCM, centrifuged at
400 × g for 10 minutes, washed twice in Hank’s balanced
salt solution (HBSS), and counted with a hemocytometer,
as described previously [36].
Adipose-derived stem cells

Frozen vials of approximately 1 × 106 ASCs were obtained
from four separate donors from the Pennington Biomedical Research Center with written, informed consent under
the same protocols approved by the Pennington Biomedical Research Center Institutional Review Board.
Vials were thawed, plated on 150 cm2 culture dishes
(Nunc) in 25 ml CCM, and incubated at 37.5°C with 5%
humidified CO2. After 24 hours, the media were removed
and adherent, viable cells were washed twice with PBS,
harvested with 0.25% trypsin/1 mM EDTA (Gibco), and
replated at 100 cells/cm2 in CCM. Media was changed
every 3 to 4 days. For all experiments, subconfluent cells
(≤70% confluent) between passages 2 and 6 were used and
grown under the same conditions as BMSCs.
Experimental autoimmune encephalitis induction and
treatment protocols

All animal experiments were approved by Tulane University School of Medicine’s Institutional Animal Care
and Use Committee and were conducted in accordance
with the US Public Health Service Policy on Human
Care and Use of Laboratory Animals.
Female C57Bl/6J mice, 6 to 8 weeks old, were purchased from Charles River Laboratories (Wilmington,
MA, USA). Chronic EAE was induced in these animals
by subcutaneous immunization with 200 μl of 200 ng
myelin oligodendrocyte glycoprotein (35–55) (Anaspec,
San Diego, CA, USA) mixed 1:1 in complete Freund’s
adjuvant with 8 mg/ml Mycobacterium tuberculosis
H35RA (Difco, Detroit, MI, USA). About 100 μl was
injected subcutaneously at each side of the base of the
tail. Mice also received 100 μl of 200 ng pertussis toxin
(List Biological Laboratories, Campbell, CA, USA) by
intraperitoneal injection concomitantly and again 2 days
later. Cells were pooled together per treatment (with approximately the same number of cells per donor) and
100 μl of 1 × 106 cells suspended in HBSS were injected
with a 27-gauge needle into the left side of the peritoneal
cavity during EAE induction (day 0; Additional file 1).
Sham-treated, EAE-induced mice received equal volumes
of HBBS without cells.
Clinical scoring and statistical analysis

Naïve mice (n = 12), EAE sham-treated mice (n = 12),
EAE mice treated with BMSCs (n = 10), EAE mice
treated with ASCs (n = 12), and EAE mice treated with
SVF (n = 12) were monitored daily for clinical signs of
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disease by three independent, blinded investigators. Clinical scores were based on a scale of 0 to 5 (0, no disease;
1, limp tail (loss of tail tone); 2, hind limb weakness;
3, partial hind limb paralysis; 4, complete hind limb paralysis; and 5 moribund or dead). No animals were excluded from analysis. Clinical scores are presented as the
mean ± standard error of the mean for each group, with
dead animals given a score of 5 on the day of death and
for the remainder of the experiment. Using GraphPad
Prism version 4.0b (GraphPad Software Inc., San Diego,
CA, USA, USA), statistical analysis on days 10 to 14 and
again on days 26 to 30 was determined by one-way analysis of variance followed by pairwise comparisons of the
mouse groups using Bonferroni post-hoc testing. Significance for the overall group effect and individual pairwise
comparisons was defined as P < 0.05. The disease onset,
disease incidence, and mean maximum scores were recorded for each mouse and expressed as the mean ±
standard deviation. The cumulative disease score was
calculated by summing the daily clinical score for each
mouse during the course of observation.
Tissue processing and histological analysis

Thirty days post disease induction, five animals per
group were euthanized by exposure to CO2 and perfused
with sterile PBS. Spinal cords were removed, postfixed
in 10% formalin (Thermo Fisher Scientific, Waltham,
MA, USA) and then embedded in paraffin. Sections
were cut at 6 μm thickness on a microtome and stained
for hematoxylin and eosin (Thermo Fisher) to reveal
perivascular inflammatory infiltrates and luxol fast blue/
cresyl violet (IHC World, Ellicott City, MD, USA) and
toluidine blue (Thermo Fisher) for myelin detection.
Histological analysis was performed on a Nikon Eclipse
E800 (Nikon, Melville, NY, USA) microscope, acquired
with Slidebook version 5.0 software (Olympus, Center
Valley, PA, USA) and analyzed using Fiji/Image J software. Quantification for each stain was performed on
nine random sections per animal and five animals per
group. All images were analyzed by investigators that
were blinded to the status of the animal. The demyelination score was measured by the ratio of area of intact
myelin against the same values for the naïve group,
which is set to 1. An index of cellular debris was determined by the percent of positive pixels divided by the
percent of positive pixels for the naïve group, which is
set to 1. The percent of inflammatory infiltrates was
measured by the number of total cells (that is, cells
5 μm2) per field at 400× magnification.
Cytokine detection

At 30 days post disease induction, blood was collected
from all mice during intracardial perfusions. Cytokines
were analyzed by enzyme-linked immunosorbent assay
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immunoassay (Life Technologies, Grand Island, NY,
USA), according to the manufacturer’s instructions.
Briefly, serum was added in 96-well precoated plates and
incubated at room temperature. After washing, a specific
polyclonal antibody followed by substrate solution was
added, and the color development was measured at
450 nm on a fluorescent microplate reader (FLUOstar
optima; BMG Labtech Inc., Durham, NC, USA). The
concentration of cytokines was calculated using the
standard curve. Statistical analysis using a two-tailed
Student’s t test was performed to evaluated differences
between groups. Significance was assumed if P ≤ 0.05.

Results
Intraperitoneal injection of human cells ameliorates
myelin oligodendrocyte glycoprotein (35–55)-induced
EAE

To evaluate whether the human cells could affect disease
progression in an autoimmune disease such as EAE, a
preventative protocol was investigated in which cells
were administered intraperitoneally at the time of disease
induction. BMSC-treated, ASC-treated, and SVF-treated
groups halted disease progression when compared with
HBSS-treated controls, resulting in a statistically significant reduction of cumulative disease scores (Figure 1,
Table 1). Although treatment groups developed the first
clinical signs of disease at the same time as the control
group, the mean maximum score was reduced in all
treatment groups (Figure 1, Table 1). Furthermore, the
disease incidence was significantly reduced in the ASC
and SVF groups (75% and 83%, respectively) (Figure 1,
Table 1). These data suggest that intraperitoneal injection of human BMSCs, ASCs, or SVF cells did not alter
the timing of the onset of disease but did result in
reduced disease severity. Moreover, it also indicates
that the therapeutic effect is similar between all three
treatment groups.
Pathological features are diminished with cell therapy

To determine whether the reduced disease severity correlated with pathological features, spinal cords from naïve
mice, HBSS-treated mice, BMSC-treated mice, ASCtreated mice, and SVF-treated EAE mice were stained
with luxol fast blue to analyze regions of demyelination.
Quantification was performed on nine sections per animal
and five animals per group. All images were analyzed by
investigators blinded to the status of the animal. Indexes
were normalized to the average value obtained in naïve
mice (set to 1). The extent of demyelinated regions was
reduced in all treatment groups compared with HBSStreated mice (Figure 2, Table 1). Similarly, all treatment
groups were stained with toluidine blue and demonstrated
reduced myelin breakdown products and debris compared
with controls (an index of 1.5 ± 0.9 in BMSC-treated mice,
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Figure 1 Preventative administration of human cell therapy reduces the clinical score of myelin oligodendrocyte glycoprotein
(35–55)-induced experimental autoimmune encephalitis. Improved clinical scores were seen in bone-derived marrow stromal cell
(BMSC)-treated (n = 10), adipose stem cell (ASC)-treated (n = 12), and stromal vascular fraction (SVF)-treated (n = 12) mice compared with controls
(n = 12). (A) Values are means from three independent reviewers. Bars, ± standard error of the mean. *P ≤ 0.05, comparing controls and treated
mice. (B) The clinical scores at day 14 days post disease induction show the distribution during peak disease, demonstrating that the majority
of treated mice displayed less severe symptoms (left panel). The clinical scores at the end of the course demonstrate that the treated groups
stably maintained their reduced state of disease (right panel).

1.3 ± 1.5 in ASC-treated mice, and 3.1 ± 0.9 in SVF-treated
mice compared with 6.1 ± 2.0 in HBSS-treated mice), consistent with the neuroprotective effect of all therapies in
EAE (Figure 2, Table 1). The influx of immune infiltrates
was measured by hematoxylin and eosin staining of spinal

cords. The percentage of infiltrating cells was significantly
decreased in animals treated with BMSCs (7.3 ± 4.9%),
ASCs (5.1 ± 4.8%) or SVF (6.7 ± 4.4%) compared with
HBSS-treated mice (14.6 ± 6.6%), indicating that all cell
treatments effectively reduced the level of inflammatory

Table 1 Clinical–pathological features of experimental autoimmune encephalitis mice and treatment groups
Treatment

Disease onset,
DPI (range)

Disease incidence,
n/n total (%)

Mean maximum
score (range)

Cumulative
disease score

Inflammatory
area (%)

Demyelinated
area (%)

Axonal
loss (%)

Control

9.0 ± 1.0 (7 to 10)

12/12 (100)

3.5 ± 0.5 (3 to 4)

30.4 (±9.57)

14.62 ± 6.6

0.68 ± 0.3†

6.1 ± 2.0†

BMSC

10.9 ± 1.9 (8 to 13)

10/10 (100)

2.3 ± 1.1 (1 to 4)

14.2 ± 11.8

7.3 ± 4.9

0.91 ± 0.3

1.5 ± 0.9

ASC

9.7 ± 0.9 (9 to 15)

9/12 (75)

2.6 ± 0.7 (1 to 4)

16.1 ± 7.2*

5.1 ± 4.8

0.75 ± 0.2

1.3 ± 1.5

SVF

9.3 ± 1.6 (2 to 3)

10/12 (83)

2.6 ± 0.7 (1 to 4)

10.8 ± 6.4*

6.7 ± 4.4

0.76 ± 0.2

3.1 ± 0.9

ASC, adipose stem cell; BMSC, bone-derived marrow stromal cell; DPI, days post disease induction; SVF, stromal vascular fraction. *P ≤ 0.05 between control group
and ASC-treated group and SVF-treated group. †P ≤ 0.05 between control group and experimental groups.
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Figure 2 Treatment with human cell therapy reduces cellular infiltration and tissue damage in experimental autoimmune encephalitis.
Spinal cords from Hank’s balanced salt solution (HBSS)-treated mice, bone-derived marrow stromal cell (BMSC)-treated mice, adipose stem cell
(ASC)-treated mice, stromal vascular fraction (SVF)-treated mice, and naïve mice were obtained after euthanasia at 30 days post disease induction
and processed for histological staining using luxol fast blue (LFB), toluidine blue (TB), and hematoxylin and eosin (H&E). LFB staining identified
multiple areas of demyelination in HBSS-treated experimental autoimmune encephalitis (EAE) mice but only scattered foci in treatment groups.
Similarly, sections labeled with TB showed increased myelin debris and greater numbers of demyelinated axons in the control mice compared
with naïve or treated mice. Comparisons of the H&E images show a decrease in the number of infiltrating immune cells in the spinal cord after
administration of both ASC and SVF.

infiltrates into the CNS during the course of EAE disease
(Figure 2, Table 1).
The stromal vascular fraction and adipose stem cells
both suppressed IFNγ and interleukin-12 in the sera of
EAE mice

Tumor necrosis factor alpha (TNFα), interleukin (IL)-12,
and IFNγ are cytokines shown to be responsible for Thelper type-1 (Th1) cell stimulation that play a central role
in the pathogenesis of MS and EAE [33,37]. To determine
whether the protective effects of the cell therapy were related to these reduced levels of these factors, cytokine levels
in the sera were assayed by enzyme-linked immunosorbent
assay. Although the IFNγ sera levels of BMSC-treated mice
(50.09 ± 9.0 pg/ml), ASC-treated mice (48.12 ± 8.5 pg/ml)

and SVF-treated mice (48.59 ± 7.8 pg/ml) were lower than
the untreated control (77.71 ± 10.0 pg/ml) (P < 0.01), the
cell-treated groups were not statistically significant among
each other (Figure 3). The IL-12 sera levels were significantly decreased in the BMSC-treated mice (193.45 ±
11.6 pg/ml) and further decreased in the SVF-treated mice
(136.23 ± 35.1 pg/ml) compared with untreated control
mice (235.18 ± 12.0 pg/ml) (P < 0.01), but the ASC-treated
mice (210.42 ± 37.8 pg/ml) were unchanged (Figure 3). The
levels of TNFα were not significantly reduced in any experimental group at this time point (Figure 3). Collectively,
these data suggest that all three treatment groups have a
similar ability to reduce levels of IFNγ, an important Th1
inflammatory cytokine, in the sera, while BMSC and SVF
treatment can also decrease IL-12 levels.
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Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Serum levels of inflammatory cytokines in naïve and treated mice with experimental autoimmune encephalitis. At 30 days
post disease induction, blood was collected from mice during intracardial perfusion and analyzed by enzyme-linked immunosorbent assay
immunoassay for interleukin (IL)-12, interferon (IFN)γ, and tumor necrosis factor alpha (TNFα). IL-12 levels were decreased in bone-derived marrow
stromal cell (BMSC)-treated mice and further decreased in stromal vascular fraction (SVF)-treated mice compared with control mice (middle panel),
while adipose stem cell (ASC)-treated mice were not significantly decreased. All treatment groups had a similar decrease in levels of IFNγ (upper
panel). No difference was seen in TNFα (bottom panel). Bars, ± standard deviation, *P ≤ 0.05.

Discussion
MSCs are a promising therapy for the treatment of
CNS-related autoimmune diseases due to their immunomodulatory and neuroprotective effects. However, the
source and availability of MSCs is becoming a crucial
issue for their clinical application. BMSCs, the most
studied MSCs, have demonstrated the ability to ameliorate both chronic and relapsing-remitting EAE [38-40].
Although BMSCs have demonstrated promising results,
the invasive nature of bone marrow biopsies may limit
their practicality for wider clinical applications. Adipose
tissue has become an appealing cell source for regenerative medicine and tissue engineering, since it contains a
large number of ASCs, is easy to obtain in large volumes, and is easily accessible [41-44]. ASCs have been
shown to hold many of the same properties as BMSCs,
such as the ability to differentiate, inhibit T-cell activation and proliferation, produce anti-inflammatory molecules, and aid in tissue repair through the secretion of
cytokines [45].
Despite the promising potential of ASCs, the need for
ex vivo cellular expansion still presents a significant
challenge for human applications. The uncultured counterpart of ASCs, the SVF, is a particularly promising candidate for regenerative medicine because the cells can be
isolated within hours of obtaining the lipoaspirate and
no culture expansion of the cells is required, which
would reduce any potential risks associated with growing
cells in vitro and remove the need for specialized laboratories. In addition to the clinical risks of ex vivo expansion, the variables used in cell culture, such as percent
and source of serum used, type of basal media, media
supplements, culture surface substrate, cell seeding
density, passage number, and confluency of culture, are
undoubtedly giving way to contrasting and confusing results in research.
Adipose tissue comprises one of the largest organs in
the body and serves as an important endocrine organ
regulating many facets of homeostasis [26,46,47]. Comprised of mature adipocytes and other nonadipocyte
cells, adipose tissue can be manually disrupted and/or
treated with collagenase to isolate the SVF. Although
not a fully defined cell population, the SVF includes vascular smooth muscle cells, fibroblasts, mast cells, macrophages, lymphocytes, endothelial cells, pre-adipocytes,
and ASCs [48-52].

SVF cells have been used clinically to treat acute and
chronic diseases afflicting a range of tissues and organs,
including soft tissue defects, breast reconstruction, and
autoimmune diseases such as graft-versus-host-disease,
rheumatoid arthritis, and Crohn’s disease [27,30,41,46,53].
To date only one group has demonstrated improved function in MS patients treated with SVF; however, mechanisms behind the improvements were not explored [30].
Similarly, only one study showed that culture-expanded
murine ASCs had a significant beneficial effect on chronic
EAE by acting simultaneously in the lymphoid organs as
well as the inflamed CNS and causing a dramatic change
in antigen-specific T cells [33]. This present study is the
first to investigate human ASCs and SVF cells in the treatment of EAE. Although SVF cells had similar mean maximum disease scores and time of disease onset to ASCs,
the SVF had lower cumulative disease score. We previously compared the ability of murine SVF with ASCs in
the same EAE model and showed that the SVF effectively
inhibited disease severity and was statistically more effective than ASCs [54]. Unlike the human SVF, which had a
disease incidence of 10 out of 12 mice (Table 1), the murine SVF only had 3 out of 12 mice demonstrate clinical
signs [54]. EAE mice treated with human SVF had a disease onset of 9.3 ± 1.6 (Table 1) while EAE mice treated
with murine SVF had a disease onset of 15 ± 4.5 days post
disease induction (unpublished findings). The disparate
results between human and mouse SVF may be due to
species differences or some undefined mechanism(s). The
current results show that uncultured SVF can ameliorate
clinical symptoms as well as reduce spinal cord inflammation, demyelination, and axonal damage without the dangers associated with ex vivo cellular expansion.
Furthermore, SVF treatment had a similar effect on
the systemic immune response in EAE mice. IFNγ is a
cytokine associated with a number of autoinflammatory
and autoimmune diseases, due to its role in Th1 cell
stimulation, differentiation, and function via STAT1 and
STAT4 pathways [37]. These autoreactive T cells play a
central role in the direct regulation of T-cell activation
and survival during autoimmune inflammation in the
pathogenesis of MS and EAE [37,55]. In this study, IFNγ
was reduced comparably between treatment groups.
These results point to the ability of SVF cells to play an
effector role similar to that of both ASCs and BMSCs,
which would occur during the early inflammatory phase
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of disease, supporting the possibility that uncultured
SVF cells could also affect the generation of encephalitogenic effector T cells. Although BMSCs have been shown
to reduce levels of IFNγ by direct contact, it is unclear
whether ASCs and SVF cells utilize the same mechanism
[56]. Although the mechanisms mediating such effects
are still only partially understood, it is likely that they involve both direct cell-to-cell contact and paracrine signaling through soluble factors.
In addition to IFNγ, IL-12 is responsible for Th1 cell
stimulation, differentiation, and function and plays a
central role in the pathology of MS [37]. In this study,
IL-12 was reduced in the BMSC-treated group and further reduced in the SVF-treated group. Although this is
the first study to show that SVF treatment reduced the
levels of IL-12, BMSCs have been shown to reduce levels
of IL-12 in a chronic EAE model [56,57]. Interestingly,
murine BMSCs were shown to exert opposing effects on
Th1 cells depending on the time of disease onset and
the level of effector T-cell activation, suppressing all T
cells when administered early during T-cell activation
and able to decrease IFNγ and increase IL-17 once T
cells become activated [58]. These results indicate that
IL-12 may play an important mechanistic role during
the increased potency of SVF-based therapy. It is possible that the SVF cells, beyond their ex vivo expanded
ASC counterpart, have the ability to further reduce the
level of effector T-cell activation, keeping the disease in
a more naïve state by reducing IL-12, and therefore Th1
stimulation and differentiation. Whether this is a result
of the ASCs being uncultured and retaining more of
their in vivo properties, is a result of the SVF being administered in a heterogeneous population, or is a product resulting from the interaction of ASCs with one of
the other cell types present remains unclear.
Although BMSCs have been shown to reduce TNFα
levels by direct contact in vitro, this study showed that intraperitoneal injection of neither BMSCs, ASCs, or SVF
cells affected TNFα levels in an EAE model [48]. This may
be due to the BMSCs being injected locally, murine
BMSCs utilizing a different mechanism, or the studies being administered at a different time points during T-cell
activation and differentiation. This also reiterates the
speculation that the timing of stem cell interaction with T
cells may drastically change immunomodulatory results
and, therefore, disease progression.
These results point to the ability of all three cell types
to play an effector role, which would occur during the
early inflammatory phase of disease. Although the mechanisms mediating such effects are still only partially
understood, it is likely that they involve both direct cellto-cell contact and paracrine signaling through soluble
factors. Further work needs to address whether the treatments utilized similar or unique mechanisms. This work
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also reiterates the speculation that the timing of cell
therapy may drastically change immunomodulatory results and, therefore, disease progression. Further work
needs to address cell therapy efficacy and cytokine response during the course of the disease, paying particular attention to cytokines that change quickly after cell
treatment, such as T-helper type-17 cells. Although
these data demonstrate that BMSCs, ASCs, and the SVF
could affect the generation of encephalitogenic effector
T cells, whether they can affect viability and function of
the encephalitogenic effector T cells in established disease still needs to be determined.

Conclusion
There is an increasing interest in the biology and therapeutic potential of the SVF due to the direct and rapid isolation procedure in a xenobiotic-reduced environment
[41,42,51]. Whether the potency of the SVF is a result of
the fact that the cells do not undergo extensive ex vivo
culture because the injected cells are a mix of ASCs in
combination with lymphohematopoietic and other cell
types or a combination of both needs to be further determined. Regardless, the findings demonstrate that when
compared with ex vivo expanded ASCs, SVF cells are
equivalent to cultured cells in their ability to ameliorate
EAE disease progression, and further reduce Th1-type cytokines. Moreover, the SVF is simple and straightforward
to isolate. The SVF cells have relevant therapeutic potential in an animal model of chronic MS and might represent a valuable tool for stem cell-based therapy in chronic
inflammatory disease of the CNS.
Additional file
Additional file 1: Figure S1. Showing a schematic of the EAE
induction and treatment protocol. Chronic EAE was induced in mice by
subcutaneous immunization with 200 μl of 200 ng myelin
oligodendrocyte glycoprotein (35–55) mixed 1:1 in complete Freund’s
adjuvant with 8 mg/ml Mycobacterium tuberculosis H35RA. About 100 μl
was injected subcutaneously at each side of the base of the tail on day 0.
Mice also received 100 μl of 200 ng pertussis toxin on day 0 and a
booster on day 2. Cells were administered in a preventative disease
setting by injecting 100 μl of 1 × 106 cells suspended in HBSS into the
left side of the peritoneal cavity during EAE induction (day 0).
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